Omaveloxolone Capsules, 2.5 mg + Omaveloxolone Capsules, 5 mg + Omaveloxolone Capsules, 10 mg + Placebo + Omaveloxolone Capsules, 20 mg + Omaveloxolone Capsules, 40 mg + Omaveloxolone Capsules, 80 mg + Omaveloxolone Capsules, 160 mg + Omaveloxolone Capsules, 300 mg + Omaveloxolone Capsules, 150 mg
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Friedreich Ataxia
Conditions
Friedreich Ataxia
Trial Timeline
Jan 31, 2015 → Dec 19, 2025
NCT ID
NCT02255435About Omaveloxolone Capsules, 2.5 mg + Omaveloxolone Capsules, 5 mg + Omaveloxolone Capsules, 10 mg + Placebo + Omaveloxolone Capsules, 20 mg + Omaveloxolone Capsules, 40 mg + Omaveloxolone Capsules, 80 mg + Omaveloxolone Capsules, 160 mg + Omaveloxolone Capsules, 300 mg + Omaveloxolone Capsules, 150 mg
Omaveloxolone Capsules, 2.5 mg + Omaveloxolone Capsules, 5 mg + Omaveloxolone Capsules, 10 mg + Placebo + Omaveloxolone Capsules, 20 mg + Omaveloxolone Capsules, 40 mg + Omaveloxolone Capsules, 80 mg + Omaveloxolone Capsules, 160 mg + Omaveloxolone Capsules, 300 mg + Omaveloxolone Capsules, 150 mg is a phase 2 stage product being developed by AbbVie for Friedreich Ataxia. The current trial status is completed. This product is registered under clinical trial identifier NCT02255435. Target conditions include Friedreich Ataxia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02255435 | Phase 2 | Completed |
Competing Products
20 competing products in Friedreich Ataxia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Prednisolone | Astellas Pharma | Phase 1 | 33 |
| Interferon γ-1b | Amgen | Phase 3 | 76 |
| interferon γ-1b | Amgen | Phase 3 | 76 |
| Interferon γ-1b + Placebo | Amgen | Phase 3 | 76 |
| varenicline + placebo | Pfizer | Phase 2/3 | 64 |
| Lu AA24493 + Placebo | Lundbeck | Phase 2 | 49 |
| Omaveloxolone | Biogen | Pre-clinical | 20 |
| Omaveloxolone | Biogen | Phase 1 | 30 |
| Omaveloxolone | Biogen | Pre-clinical | 20 |
| Omaveloxolone + Placebo | Biogen | Phase 3 | 74 |
| Omeveloxolone | Biogen | Pre-clinical | 20 |
| TAK-831 + TAK-831 Placebo | Neurocrine Biosciences | Phase 2 | 49 |
| EGb 761 120 mg + Placebo | Ipsen | Phase 2 | 49 |
| Vatiquinone + Placebo | PTC Therapeutics | Phase 2/3 | 62 |
| Placebo + EPI-743 400 mg + EPI-743 200 mg | PTC Therapeutics | Phase 2 | 49 |
| Vatiquinone | PTC Therapeutics | Phase 2 | 49 |
| Vatiquinone | PTC Therapeutics | Phase 3 | 74 |
| DT-216 + Placebo | Design Therapeutics | Phase 1 | 28 |
| DT-216P2 + Saline | Design Therapeutics | Phase 1 | 28 |
| DT-216 + DT-216 matching Placebo | Design Therapeutics | Phase 1 | 28 |